Table 1.
Demographics of the whole cohort (n = 2483), training set (n = 781 control and CRC samples) and validation set (n = 384 control and CRC samples).
| Participating individuals | ||||||
|---|---|---|---|---|---|---|
| Study | Total | Control* | Other cancers** | CRC | ||
| N | 2483 | 573 | 1113 | 797 | ||
| Age (years), mean (SD) | 64.19(9.11) | 62.24(8.99) | 63.97(8.79) | 65.70(9.37) | ||
| Female gender, n (%) | 1283 (51.67%) | 318 (55.50%) | 559 (50.22%) | 406 (50.94%) | ||
| Ethnicity, n (%) | ||||||
| Asian | 270 (10.87%) | 61 (10.65%) | 122 (10.96%) | 87 (10.92%) | ||
| Black/African American | 52 (2.09%) | 12 (2.09%) | 39 (3.50%) | 1 (0.13%) | ||
| Pacific Islander | 55 (2.22%) | 0 (0.00%) | 1 (0.09%) | 54 (6.78%) | ||
| Other | 274 (11.04%) | 104 (18.15%) | 62 (5.57%) | 108 (13.55%) | ||
| Unknown | 23 (0.93%) | 0 (0.00%) | 16 (1.44%) | 7 (0.88%) | ||
| White | 1809 (72.86%) | 396 (69.11%) | 873 (78.44%) | 540 (67.75%) | ||
| Control* | CRC | CRC stage 1 | CRC stage 2 | CRC stage 3 | CRC stage 4 | |
|---|---|---|---|---|---|---|
| Training set | ||||||
| N | 316 | 465 | 91 | 189 | 135 | 50 |
| Age, years, mean (SD) | 61.74 (8.89) | 65.51 (9.13 | 66.20 (8.20) | 65.78 (9.31) | 65.19 (9.78) | 64.06 (8.22) |
| Female gender, n (%) | 174 (55.06%) | 244 (52.47%) | 50 (54.95%) | 98 (51.85%) | 70 (51.85%) | 26 (52.00%) |
| Ethnicity, n (%) | ||||||
| Asian | 15 (4.75%) | 51 (10.97%) | 16 (17.58%) | 13 (6.88%) | 18 (13.33%) | 4 (8.00%) |
| Black/African American | 10 (3.16%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Pacific Islander | 0 (0.00%) | 26 (5.59%) | 3 (3.30%) | 23 (12.17%) | 0 (0.00%) | 0 (0.00%) |
| Other | 71 (22.47%) | 73 (15.70%) | 2 (2.20%) | 28 (14.81%) | 30 (22.22%) | 13 (26.00%) |
| Unknown | 0 (0.00%) | 5 (1.08%) | 0 (0.00%) | 5 (2.65%) | 0 (0.00%) | 0 (0.00%) |
| White | 220 (69.62%) | 310 (66.67%) | 70 (76.92%) | 120 (63.49%) | 87 (64.44%) | 33 (66.00%) |
| Validation set | ||||||
| N | 164 | 220 | 45 | 87 | 61 | 27 |
| Age (years), mean (SD) | 65.88 (9.64) | 62.46 (9.24) | 64.31 (7.54) | 66.41 (10.05) | 65.49 (10.29) | 67.63 (10.00) |
| Female gender, n (%) | 95 (57.93%) | 116 (52.73%) | 21 (46.67%) | 49 (56.32%) | 35 (57.38%) | 11 (40.74%) |
| Ethnicity, n (%) | ||||||
| Asian | 10 (6.10%) | 24 (10.91%) | 5 (11.11%) | 8 (9.20%) | 6 (9.84%) | 5 (18.52%) |
| Black/African American | 1 (0.61%) | 1 (0.45%) | 0 (0.00%) | 1 (1.15%) | 0 (0.00%) | 0 (0.00%) |
| Pacific Islander | 0 (0.00%) | 15 (6.82%) | 2 (4.44%) | 13 (14.94%) | 0 (0.00%) | 0 (0.00%) |
| Other | 30 (18.29%) | 24 (10.91%) | 0 (0.00%) | 5 (5.75%) | 14 (22.95%) | 5 (18.52%) |
| Unknown | 0 (0.00%) | 1 (0.45%) | 0 (0.00%) | 1 (1.15%) | 0 (0.00%) | 0 (0.00%) |
| White | 123 (75.00%) | 155 (70.45%) | 38 (84.44%) | 59 (67.82%) | 41 (67.21%) | 17 (62.96%) |
*Control samples were from individuals with conditions including rheumatoid arthritis, COPD and peptic ulcer.
**Other cancer samples were from individuals with the following cancers: advanced adenoma, breast cancer, lung cancer, non-advanced adenoma, ovarian cancer, prostate cancer, stomach cancer, urinary cancer.